- Home
- SGN vs SNPX Comparison
SGN vs SNPX Comparison
Compare SGN & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- SNPX
- Stock Information
- Founded
- SGN 2019
- SNPX 2012
- Country
- SGN United States
- SNPX United States
- Employees
- SGN N/A
- SNPX N/A
- Industry
- SGN
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- SGN
- SNPX Health Care
- Exchange
- SGN Nasdaq
- SNPX Nasdaq
- Market Cap
- SGN 3.8M
- SNPX 3.1M
- IPO Year
- SGN 2023
- SNPX N/A
- Fundamental
- Price
- SGN $1.04
- SNPX $8.35
- Analyst Decision
- SGN
- SNPX Strong Buy
- Analyst Count
- SGN 0
- SNPX 1
- Target Price
- SGN N/A
- SNPX N/A
- AVG Volume (30 Days)
- SGN 863.1K
- SNPX 2.7M
- Earning Date
- SGN 08-18-2025
- SNPX 08-13-2025
- Dividend Yield
- SGN N/A
- SNPX N/A
- EPS Growth
- SGN N/A
- SNPX N/A
- EPS
- SGN N/A
- SNPX N/A
- Revenue
- SGN $529,282.00
- SNPX N/A
- Revenue This Year
- SGN N/A
- SNPX N/A
- Revenue Next Year
- SGN N/A
- SNPX N/A
- P/E Ratio
- SGN N/A
- SNPX N/A
- Revenue Growth
- SGN 8.42
- SNPX N/A
- 52 Week Low
- SGN $0.44
- SNPX $1.84
- 52 Week High
- SGN $36.70
- SNPX $7.85
- Technical
- Relative Strength Index (RSI)
- SGN 49.29
- SNPX 78.58
- Support Level
- SGN $1.01
- SNPX $3.25
- Resistance Level
- SGN $1.35
- SNPX $4.44
- Average True Range (ATR)
- SGN 0.15
- SNPX 1.13
- MACD
- SGN -0.02
- SNPX 0.42
- Stochastic Oscillator
- SGN 27.40
- SNPX 95.15
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.